Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase (`MACS1252)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: February 1, 2010
Last updated: October 2, 2014
Last verified: October 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)